Similar articles

• Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.

  Ma Z, Liu H, Wu B. Ma Z, et al. Br J Clin Pharmacol. 2014 Mar;77(3):410-20. doi: 10.1111/bcp.12169. Br J Clin Pharmacol. 2014. PMID: 23713800 Free PMC article. Review.
• Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.

  Ellermann M, Paulini R, Jakob-Roetne R, Lerner C, Borroni E, Roth D, Ehler A, Schweizer WB, Schlatter D, Rudolph MG, Diederich F. Ellermann M, et al. Chemistry. 2011 May 27;17(23):6369-81. doi: 10.1002/chem.201003648. Epub 2011 Apr 27. Chemistry. 2011. PMID: 21538606
• Molecular recognition at the active site of catechol-o-methyltransferase: energetically favorable replacement of a water molecule imported by a bisubstrate inhibitor.

  Ellermann M, Jakob-Roetne R, Lerner C, Borroni E, Schlatter D, Roth D, Ehler A, Rudolph MG, Diederich F. Ellermann M, et al. Angew Chem Int Ed Engl. 2009;48(48):9092-6. doi: 10.1002/anie.200904410. Angew Chem Int Ed Engl. 2009. PMID: 19882607 No abstract available.
• Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.

  Tsuji E, Okazaki K, Takeda K. Tsuji E, et al. Biochem Biophys Res Commun. 2009 Jan 16;378(3):494-7. doi: 10.1016/j.bbrc.2008.11.085. Epub 2008 Dec 3. Biochem Biophys Res Commun. 2009. PMID: 19056347
• Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

  Männistö PT, Kaakkola S. Männistö PT, et al. Pharmacol Rev. 1999 Dec;51(4):593-628. Pharmacol Rev. 1999. PMID: 10581325 Review. No abstract available.